Home
Drugs
Fulvestrant

Fulvestrant

Drug

Drug Profile

Fulvestrant is an antiestrogen medication and selective estrogen receptor degrader (SERD) used for hormone receptor-positive advanced or metastatic breast cancer. It is administered by intramuscular injection and is marketed under the brand name Faslodex. Fulvestrant was approved for medical use in the United States in 2002.

Drug Class: Estrogen receptor antagonist (SERD; hormonal antineoplastic)
Approval Status: FDA approved; first approved April 25, 2002.
Mechanism of Action: Binds the estrogen receptor and destabilizes it, promoting receptor degradation.

Brand Names

Faslodex

Indications

\Hormone receptor-positive metastatic breast cancer\
\HR-positive, HER2-negative advanced breast cancer (including combination endocrine regimens)\

Related News

Oncology Pipeline Update: Prostate Cancer T-Cell Engager Partnership, BTK Inhibitor Filing, and Novel Targeted Therapy Results

Jun 05, 2026

Key oncology developments include a $315 million partnership between Astellas and Vir for the prostate cancer T-cell engager VIR-5500, with updated phase 1 data showing an 82% PSA50 rate. The FDA accepted a filing for Ono Pharmaceuticals' tirabrutinib seeking accelerated approval in primary central nervous system lymphoma. Research findings also identified a new kidney cancer biomarker and showed promising results for the TRK inhibitor repotrectinib and the breast cancer triple therapy gedatolisib plus palbociclib and fulvestrant.

Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer

May 07, 2026

Sensei Biotherapeutics dosed the first patient in a Phase 1b/2 trial of PIKTOR (sapanisertib + serabelisib) in HR+/HER2- advanced breast cancer. The multi-node PI3K/AKT/mTOR inhibitor previously showed a 47% overall response rate in a Phase 1b trial.

Gedatolisib combinations beat alpelisib regimen in PIK3CA-mutant HR-positive breast cancer

May 05, 2026

Topline phase 3 VIKTORIA-1 results showed gedatolisib combinations improved progression-free survival versus alpelisib plus fulvestrant in PIK3CA-mutant HR-positive/HER2-negative advanced breast cancer. Celcuity plans a supplemental FDA filing based on the data.

FDA Accepts NDA for Vepdegestrant, First PROTAC to Reach Regulatory Review in Breast Cancer

May 02, 2026

FDA has accepted the NDA for vepdegestrant (ARV-471), an oral PROTAC ER degrader from Arvinas and Pfizer, for ESR1-mutated ER+/HER2- advanced breast cancer. A PDUFA date of June 5, 2026 has been set. The submission is based on positive Phase 3 VERITAC-2 data.

SONIA Trial Finds No Overall Survival Benefit for First-Line CDK4/6 Inhibitors in Advanced Breast Cancer

Apr 02, 2026

The SONIA trial found no overall survival benefit for first-line CDK4/6 inhibitors versus second-line use in advanced HR+/HER2- breast cancer. Median survival was 47.9 vs 48.1 months, though post hoc analysis suggested benefit in premenopausal patients. First-line treatment was associated with more severe adverse events.

Phase 3 Breast Cancer Trial Data Highlights from Q1 2026

Apr 01, 2026

Multiple phase 3 breast cancer trials reported significant findings in early 2026, including positive results for novel therapies across different subtypes. Key data includes progression-free survival benefits for palbociclib in HR-positive, HER2-positive advanced breast cancer and investigations of antibody-drug conjugates and combination therapies. Full trial findings are expected to be presented at upcoming medical meetings.

Novartis Acquires Pikavation for Up to $3 Billion in Cancer Pipeline Expansion

Mar 23, 2026

Novartis will acquire Pikavation Therapeutics for up to $3 billion to gain its PI3Kα inhibitor programs, led by SNV4818 for metastatic breast cancer. The deal includes $2 billion upfront and up to $1 billion in milestones, with completion expected in first half 2026. SNV4818 is designed to selectively target mutated PI3Kα while sparing healthy cells.

Breast Cancer Research Advances: New Drug Trials and Resistance Mechanisms Identified

Mar 20, 2026

Recent developments in breast cancer treatment include new clinical trials for advanced disease, findings on CDK4/6 inhibitor sequencing, and discovery of genetic markers explaining drug resistance in HER2-positive breast cancer.

PROTAC Technology Advances Toward Phase III Trials in Cancer Treatment

Mar 18, 2026

Proteolysis-targeting chimeras (PROTACs) are advancing from experimental to clinical-stage cancer therapies, with first candidates entering Phase III trials. The technology degrades target proteins rather than blocking them, offering new options for previously undruggable targets.

MoonLake on Track for HS BLA Submission; Relay's Zovegalisib Receives FDA Breakthrough Status

Feb 24, 2026

MoonLake Immunotherapeutics says FDA feedback indicates sufficient data to support a U.S. BLA for hidradenitis suppurativa without additional efficacy trials, while Relay Therapeutics received FDA Breakthrough Therapy designation for zovegalisib in combination with fulvestrant for PIK3CA-mutant breast cancer.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT07604571	Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer	RECRUITING	PHASE1
NCT07604272	Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal Hernias in Males	NOT_YET_RECRUITING	PHASE1
NCT07570966	Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors	NOT_YET_RECRUITING	PHASE1/PHASE2
NCT07558733	Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer	RECRUITING	PHASE1/PHASE2
NCT07480681	Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (a KAT6A/B Inhibitor) in Patients With Advanced/Metastatic Solid Tumor	NOT_YET_RECRUITING	PHASE1
NCT07426822	Rash & Diarrhea Prophylaxis With Capivasertib	NOT_YET_RECRUITING	PHASE2
NCT07408089	Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer	RECRUITING	PHASE1
NCT07405801	A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer	RECRUITING	PHASE2
NCT07368998	To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer	RECRUITING	PHASE2
NCT07366632	A Study of Single Dose of BL0175 in Postmenopausal Women	NOT_YET_RECRUITING	PHASE1